1Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [ 被引量：1
2Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplication[J]. J Clin Oncol, 2001,19(10) :2587. 被引量：1
3Baselga J, Tripathy D, Mendetsohn J, et al. Phase Ⅱ study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer[J]. J Clin Oncol, 1996,14(3) :737. 被引量：1
4Baselga J, Norton L, Albanell J, et al. Recombinant humanized antiHER2 antibody(Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J]. Cancer Res, 1998,58 (13): 2825. 被引量：1
5Kunisue H, Kurebayashi J ,Otsuki T, et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both eestrogen receptors and HER2[J]. Br J Cancer, 2000,82(1):46. 被引量：1
6Pegram MD, Lipton A, Hayes DF, et al. Phase Ⅱ study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monolnal antibody plus cisplatin in patients with HER2/neu-over-erpressing metastatic breast cancer refractory to chemo 被引量：1
7Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab[J]. Nature,2003,421 (6924) :756. 被引量：1
8Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in womenn with metastatic breast cancer[J] .J Clin Oncol,2002,20(14):3106. 被引量：1
9Salmon DJ, Leylang-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J]. N Engl J Med,2001,344(11):783. 被引量：1
10Burris HA. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer[J]. Semin Oncol,2001,28 (Supp3.1) :38. 被引量：1
